What's New

The article "A new direction or the end of the road" published in Marie Claire September 2010 issue, can be read online on the Australian Consumer Patients' Rights Group website  link  http://www.acpr.com.au/pdf/marie-claire-article.pdf .
It is about individuals who, suffering from depression, became suicidal and/or homicidal when taking antidepressants. A gene test may have prevented these disastrous side effects.

Avandia (rosiglitazone) increases the risk of heart problems.

The recurrence risk of cardiovascular events and death following clopidogrel treatment is associated with CYP2C19 genetic status.

The US Food and Drug Administration has updated the labeling for the anticoagulant warfarin with pharmacogenomically guided dosing ranges.

The recurrence risk of breast cancer in individuals treated with tamoxifen is associated with their CYP2D6 genetic status.

Plavix (clopidogrel bisulfate) 75 mg tablets

Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- May 2009

Precautions detailed in relation to Pharmacogentics and Drug Interactions.

http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm165166.htm

GenesFX launches new interactive pharmacogenomic website at the Australian Pharmacogenomic Summit.

Australian Pharmacogenomics Summit  - Set to revolutionise healthcare delivery both in Australia and across the globe, the potential for targeted therapies is huge. "In total worldwide spending on new pharmacogenomic technologies is predicted to be
more than $3.7billion in 2009" - Australian Centre for Health Research

GenesFX Health provides a pharmacogenomic testing service using a NATA accredited national pathology provider in Australia.

GenesFX publishes on TPMT testing. Sheffield,L.J.; Irving,P.; Gupta,A.; Byron,K.; Macrae,F.A.; Phillimore,H.; Dronavalli,M.; Rose,R.; George,P. hiopurine methyltransferase and thiopurine metabolite testing in patients with inflammatory bowel disease who are taking thiopurine drugs Pharmacogenomics10 1077-1081.2009 www.ncbi.nlm.nih.gov/pubmed/19604082

GenesFX Article on current pharmacogenomics tests in 2009 Click here for PDF or see at Clinical Biochemists reviews (May 2009). http://old.aacb.asn.au/pubs/2009%20cbr%20articles/may%20cbr%2009%20sheffield.pdf

New England Journal of Medicine (NEJM) - Article showing that the best way to work out warfarin dose is to use pharmacogenomic testing and this is better than using clinical information or a fixed dose. www.ncbi.nlm.nih.gov/pubmed/19228618

New England Journal of Medicine. - Article showing that the drug clopidogrel does not work as well in individuals who have abnormal pharmacogenomic test results and they have a greater risk of heart attacks and stroke. www.ncbi.nlm.nih.gov/pubmed/19106083

New clinical study investigating "Factors contributing to bleeding risk in patients receiving warfarin" conducted by GenesFX and Monash University

FDA Approves Updated Warfarin (Coumadin) Prescribing Information. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108967.htm